Withdrawal of the marketing authorisation application
On 17 February 2010, United Therapeutics Europe Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Tyvaso, intended to be used as an 'add on' treatment for patients with pulmonary arterial hypertension.
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Tyvaso (PDF/867.28 KB)Adopted
First published: 17/05/2010
Last updated: 17/05/2010
United Therapeutics Europe Ltd withdraws its marketing authorisation application for Tyvaso (PDF/47.28 KB)
First published: 19/02/2010
Last updated: 19/02/2010
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').